NASDAQ:LEGN Legend Biotech (LEGN) Stock Price, News & Analysis $18.57 -0.75 (-3.88%) Closing price 04:00 PM EasternExtended Trading$18.86 +0.29 (+1.55%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Legend Biotech Stock (NASDAQ:LEGN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Legend Biotech alerts:Sign Up Key Stats Today's Range$18.52▼$19.6450-Day Range$17.00▼$22.6052-Week Range$16.24▼$37.50Volume2.53 million shsAverage Volume2.23 million shsMarket Capitalization$3.60 billionP/E RatioN/ADividend YieldN/APrice Target$55.79Consensus RatingModerate Buy Company Overview Legend Biotech Corporation (NASDAQ: LEGN) is a biotechnology company focused on developing, manufacturing and commercializing cell therapies for cancer and other serious diseases. Its research centers on chimeric antigen receptor T-cell (CAR-T) therapies, which use genetically modified immune cells to recognize and attack cancer cells. The company’s leading product is Carvykti (ciltacabtagene autoleucel), a B-cell maturation antigen (BCMA)-directed CAR-T therapy for certain adults with relapsed or refractory multiple myeloma. Legend Biotech developed Carvykti in collaboration with Janssen Biotech, part of Johnson & Johnson, which is responsible for commercialization in collaboration with Legend in applicable markets. Founded in 2014, Legend Biotech is headquartered in Somerset, New Jersey, and maintains operations and research capabilities in the United States and China. In addition to Carvykti, the company is advancing a pipeline of investigational cell therapies designed to address hematologic malignancies and potentially other diseases.AI Generated. May Contain Errors. Read More Legend Biotech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScoreLEGN MarketRank™: Legend Biotech scored higher than 71% of companies evaluated by MarketBeat, and ranked 183rd out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingLegend Biotech has received a consensus rating of Moderate Buy. The company's average rating score is 2.53, and is based on no strong buy ratings, 9 buy ratings, 5 hold ratings, and 1 sell rating.Upside PotentialLegend Biotech has a consensus price target of $55.79, representing about 200.4% upside from its current price of $18.57.Amount of Analyst CoverageLegend Biotech has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Legend Biotech's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Legend Biotech are expected to grow in the coming year, from ($0.09) to $1.17 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Legend Biotech is -74.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Legend Biotech is -74.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLegend Biotech has a P/B Ratio of 3.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Legend Biotech's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.56% of the float of Legend Biotech has been sold short.Short Interest Ratio / Days to CoverLegend Biotech has a short interest ratio ("days to cover") of 7.09.Change versus previous monthShort interest in Legend Biotech has recently decreased by 11.16%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLegend Biotech does not currently pay a dividend.Dividend GrowthLegend Biotech does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.33 News SentimentLegend Biotech has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Legend Biotech this week, compared to 5 articles on an average week.Search InterestOnly 5 people have searched for LEGN on MarketBeat in the last 30 days. This is a decrease of -55% compared to the previous 30 days.MarketBeat Follows8 people have added Legend Biotech to their MarketBeat watchlist in the last 30 days. This is an increase of 167% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Legend Biotech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $308,550.00 in company stock.Percentage Held by Insiders0.02% of the stock of Legend Biotech is held by insiders.Percentage Held by Institutions70.89% of the stock of Legend Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Legend Biotech's insider trading history. Receive LEGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Legend Biotech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LEGN Stock News HeadlinesLegend Biotech Faces Pressure From Rivals Ahead of Key FDA Decision, UBS Says3 hours ago | finance.yahoo.comInsider Selling: Legend Biotech (NASDAQ:LEGN) Director Sells $258,920.20 in StockOctober 2 at 5:22 AM | insidertrades.comHow Elon’s Empire Ends (and how to profit)Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg terminal, says a new micro cluster AI technology could render today's data centers, including Elon Musk's Colossus in Tennessee, obsolete for major breakthroughs. These next generation centers use 99 percent less space, electricity and water, yet Chaikin's research shows they could be more than a trillion times more powerful than the top data center on earth today, potentially cutting AI breakthrough timelines from five years to five days.October 2 at 1:00 AM | Chaikin Analytics (Ad)Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple MyelomaOctober 1 at 9:00 AM | globenewswire.comLegend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Stock Has Average Price Target of $53.14September 26, 2026 | americanbankingnews.comLegend Biotech Corporation Presents Five-Year Follow-Up Data from Cartitude-2 Cohort A Evaluating Carvykti in Patients with Relapsed/Refractory Multiple MyelomaSeptember 25, 2026 | marketscreener.comMLegend Biotech Says Five-Year Carvykti Data Show 50% of Patients Remained Progression-Free and AliveSeptember 25, 2026 | finance.yahoo.comInsider Selling: Legend Biotech (NASDAQ:LEGN) CFO Sells 5,430 SharesSeptember 24, 2026 | insidertrades.comSee More Headlines LEGN Stock Analysis - Frequently Asked Questions How have LEGN shares performed this year? Legend Biotech's stock was trading at $21.74 on January 1st, 2026. Since then, LEGN stock has decreased by 14.6% and is now trading at $18.57. How were Legend Biotech's earnings last quarter? Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) issued its quarterly earnings results on Tuesday, August, 11th. The company reported $0.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.07 by $0.02. The company's revenue for the quarter was up 51.9% on a year-over-year basis. Read the conference call transcript. When did Legend Biotech IPO? Legend Biotech (LEGN) raised $350 million in an IPO on Friday, June 5th 2020. The company issued 18,425,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley, J.P. Morgan Securities and Jefferies served as the underwriters for the IPO. How do I buy shares of Legend Biotech? Shares of LEGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Legend Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Legend Biotech investors own include NVIDIA (NVDA), Broadcom (AVGO), Adobe (ADBE), Meta Platforms (META), Arista Networks (ANET), Jabil (JBL) and e.l.f. Beauty (ELF). Company Calendar Last Earnings8/11/2026Today10/02/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 LEGN's financial health is in the Red zone, according to TradeSmith. LEGN has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:LEGN CIK1801198 Webwww.legendbiotech.com Phone732-317-5050FaxN/AEmployees2,965Year Founded2014Price Target and Rating Average Price Target for Legend Biotech$55.79 High Price Target$74.00 Low Price Target$24.00 Potential Upside/Downside+200.4%Consensus RatingModerate Buy Rating Score (0-4)2.53 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($0.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$296.80 million Net Margins-7.21% Pretax Margin-4.42% Return on Equity-8.71% Return on Assets-5.40% Debt Debt-to-Equity RatioN/A Current Ratio3.04 Quick Ratio2.94 Sales & Book Value Annual Sales$1.03 billion Price / Sales3.50 Cash FlowN/A Price / Cash FlowN/A Book Value$5.43 per share Price / Book3.42Miscellaneous Outstanding Shares193,770,000Free Float193,730,000Market Cap$3.60 billion OptionableOptionable Beta0.57 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:LEGN) was last updated on 10/2/2026 by MarketBeat.com Staff. From Our PartnersElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredA major gold reset could be closer than people thinkFor 50 years, Washington has held 8,133 tonnes of gold on its books at a fraction of today's market price. One...Reagan Gold Group | SponsoredMy next big call (under $1)Crypto traders have a name for this month... Uptober. Since 2013, Bitcoin has closed October higher in 10 of 1...Crypto 101 Media | SponsoredWATCH THIS BEFORE DECEMBER 8th!!James Altucher says a quiet government filing could reveal Elon Musk's biggest move yet, and almost nobody has...Paradigm Press | SponsoredA new kind of civil war is coming after election day?Across America, AI-driven backlash is fueling protests, lawsuits, and moratoria that could reshape the politic...Stansberry Research | SponsoredHow Elon’s Empire Ends (and how to profit)Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Legend Biotech Corporation Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Legend Biotech With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
